A cell-based assay for aggregation inhibitors as therapeutics of polyglutamine-repeat disease and validation in Drosophila

Authors:
  • AKAlexsey Kazantsev
    Alexsey Kazantsev
  • SRSimona Raffioni
    Simona Raffioni
  • KIKatalin Illes
    Katalin Illes
  • JPJudit Pallos
    Judit Pallos
  • NSNatalia Slepko
    Natalia Slepko
  • JBJames E. Bear
    James E. Bear
  • FGFrank B. Gertler
    Frank B. Gertler
  • SHSteven Hersch
    Steven Hersch
  • DHDavid E. Housman
    David E. Housman
  • JMJ. Lawrence Marsh
    J. Lawrence Marsh

Abstract
The formation of polyglutamine-containing aggregates and inclusions are hallmarks of pathogenesis in Huntington's disease that can be recapitulated in model systems. Although the contribution of inclusions to pathogenesis is unclear, cell-based assays can be used to screen for chemical compounds that affect aggregation and may provide therapeutic benefit. We have developed inducible PC12 cell-culture models to screen for loss of visible aggregates. To test the validity of this approach, compounds that inhibit aggregation in the PC12 cell-based screen were tested in a Drosophila model of polyglutamine-repeat disease. The disruption of aggregation in PC12 cells strongly correlates with suppression of neuronal degeneration in Drosophila . Thus, the engineered PC12 cells coupled with the Drosophila model provide a rapid and effective method to screen and validate compounds.

This publication has 52 references indexed in Scilit: